SCHEMBL7501602

SCHEMBL7501602

Oc1ccc(-c2ccc(-c3coc4ccccc34)cc2)cc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 7/20 0.50
NPC1 O15118 6/20 0.50
ALDH1A1 P00352 6/20 0.50
RAB9A P51151 6/20 0.50
ESR1 P03372 5/20 0.50
MAOB P27338 5/20 0.50
HPGD P15428 5/20 0.50
MAOA P21397 4/20 0.50
KDM4E B2RXH2 4/20 0.50
ESR2 Q92731 4/20 0.50
CYP3A4 P08684 3/20 0.50
TDP1 Q9NUW8 3/20 0.50
HSD17B10 Q99714 3/20 0.50
AKR1B10 O60218 2/20 0.50
LMNA P02545 2/20 0.50
TTR P02766 2/20 0.50
TP53 P04637 2/20 0.50
CYP1A2 P05177 2/20 0.50
MAPT P10636 2/20 0.50
CYP19A1 P11511 2/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL311201 0.84 MAOB (0.71) SMN1; SMN2NPC1ALDH1A1RAB9AESR1
SCHEMBL1310425 0.82 PIN1 (0.56) SMN1; SMN2NPC1ALDH1A1RAB9AMAOB
SCHEMBL7507706 0.81 MIF (0.46) SMN1; SMN2NPC1ALDH1A1RAB9AMAOB
SCHEMBL24368421 0.80 MIF (0.42) SMN1; SMN2NPC1ALDH1A1RAB9AMAOB
SCHEMBL8338813 0.79 PIN1 (0.46) NPC1MAOBMAOALMNATP53
SCHEMBL19180204 0.79 MIF (0.44) SMN1; SMN2NPC1ALDH1A1RAB9AMAOB
SCHEMBL28212036 0.79 GSK3B (0.51) SMN1; SMN2NPC1ALDH1A1RAB9AMAOB
SCHEMBL2247403 0.79 MIF (0.44) SMN1; SMN2NPC1ALDH1A1MAOBMAPT
SCHEMBL11465458 0.79 MAOB (0.46) MAOBMAOACYP1A2MAPTMIF
SCHEMBL24368656 0.78 MIF (0.43) SMN1; SMN2NPC1ALDH1A1RAB9AMAOB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1077967-B1 BIPHENYL OXO-ACETIC ACIDS USEFUL IN THE TREATMENT OF INSULIN RESISTANCE AND HYPERGLYCEMIA WYETH CORP (US) 2002-12-04 EP claimed
EP-1077967-B1 BIPHENYL OXO-ACETIC ACIDS USEFUL IN THE TREATMENT OF INSULIN RESISTANCE AND HYPERGLYCEMIA WYETH CORP (US) 2002-12-04 EP disclosed
EP-1077966-B1 BIPHENYL SULFONYL ARYL CARBOXYLIC ACIDS USEFUL IN THE TREATMENT OF INSULIN RESISTANCE AND HYPERGLYCEMIA WYETH CORP (US) 2002-11-20 EP disclosed
US-6391897-B2 (4'-BENZOFURAN-3-YL-BIPHENYL-4-YLOXY)-ACETIC ACID, FOR EXAMPLE; INHIBIT PROTEIN-TYROSINE PHOSPHATASES (PTPASES) AMERICAN HOME PRODUCTS CORPORATION 2002-05-21 US disclosed
US-6369072-B2 Biphenyl oxo-acetic acids useful in the treatment of insulin resistance and hyperglycemia AMERICAN HOME PRODUCTS CORPORATION 2002-04-09 US disclosed
US-20010053785-A1 Biphenyl oxo-acetic acids useful in the treatment of insulin resistance and hyperglycemia WYETH 2001-12-20 US disclosed
US-20010041715-A1 Biphenyl oxo-acetic acids useful in the treatment of insulin resistance and hyperglycemia AMERICAN HOME PRODUCTS 2001-11-15 US disclosed
US-6310081-B1 PROTEIN TYROSINE PHOSPHATASE INHIBITORS AMERICAN HOME PRODUCTS CORPORATION 2001-10-30 US disclosed
US-6232322-B1 SUCH AS (4'-BENZOFURAN-3-YL-BIPHENYL-4-YLOXY)-ACETIC ACID OR SALT AMERICAN HOME PRODUCTS CORPORATION 2001-05-15 US disclosed
US-6221902-B1 HYPOGLYCEMIC AGENTS; ANTIDIABETIC AGENTS AMERICAN HOME PRODUCTS CORPORATION 2001-04-24 US disclosed
EP-1077966-A1 BIPHENYL SULFONYL ARYL CARBOXYLIC ACIDS USEFUL IN THE TREATMENT OF INSULIN RESISTANCE AND HYPERGLYCEMIA AMERICAN HOME PRODUCTS CORPORATION (US) 2001-02-28 EP disclosed
EP-1077967-A2 BIPHENYL OXO-ACETIC ACIDS USEFUL IN THE TREATMENT OF INSULIN RESISTANCE AND HYPERGLYCEMIA AMERICAN HOME PRODUCTS CORPORATION (US) 2001-02-28 EP disclosed
WO-1999058518-A2 BIPHENYL OXO-ACETIC ACIDS USEFUL IN THE TREATMENT OF INSULIN RESISTANCE AND HYPERGLYCEMIA AMERICAN HOME PRODUCTS CORPORATION (US) 1999-11-18 WO disclosed
WO-1999058520-A1 BIPHENYL SULFONYL ARYL CARBOXYLIC ACIDS USEFUL IN THE TREATMENT OF INSULIN RESISTANCE AND HYPERGLYCEMIA AMERICAN HOME PRODUCTS CORPORATION (US) 1999-11-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010053785-A1 Biphenyl oxo-acetic acids useful in the treatment of insulin resistance and hyperglycemia GPR119, INSR, IAPP SMN1; SMN2 2603/4885NPC1 1076/4885ALDH1A1 350/4885
US-20010041715-A1 Biphenyl oxo-acetic acids useful in the treatment of insulin resistance and hyperglycemia GPR119, INSR, IAPP SMN1; SMN2 2603/4885NPC1 1076/4885ALDH1A1 350/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.